D. E. Shaw & Co., Inc. Karuna Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $3.28 Million - $6.47 Million	-20,353 Reduced 51.55%	19,131 $6.06 Million
Q3 2023 Nov 14, 2023	SELL	$164.66 - $218.08 $13.1 Million - $17.4 Million	-79,842 Reduced 66.91%	39,484 $6.68 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $2.1 Million - $2.86 Million	11,907 Added 11.08%	119,326 $25.9 Million
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $27.4 Million - $34.7 Million	-169,761 Reduced 61.25%	107,419 $19.5 Million
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $7.84 Million - $9.7 Million	-40,940 Reduced 12.87%	277,180 $54.5 Million

Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $38.7 Million - $86.7 Million	312,660 Added 5726.37%	318,120 $71.6 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $513,076 - $782,581	5,460 New	5,460 $691,000
Q4 2021 Feb 14, 2022	SELL	$110.64 - $159.4 $1.8 Million - $2.6 Million	-16,285 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $97,556 - $121,338	-964 Reduced 5.59%	16,285 $1.99 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $1.85 Million - $2.35 Million	17,249 New	17,249 $1.97 Million
Q3 2020 Nov 16, 2020	SELL	$71.31 - $109.74 $514,216 - $791,335	-7,211 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$62.14 - $117.21 $448,091 - $845,201	7,211 New	7,211 $804,000
Q1 2020 May 15, 2020	SELL	$60.41 - $115.92 $1.64 Million - $3.14 Million	-27,118 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $310,229 - $3.36 Million	27,118 New	27,118 $2.04 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.